Reuters logo
BRIEF-ProMIS Neurosciences designates PMN330 as 3rd, validated lead product for development in alzheimer's disease
September 13, 2017 / 11:38 AM / 3 months ago

BRIEF-ProMIS Neurosciences designates PMN330 as 3rd, validated lead product for development in alzheimer's disease

Sept 13 (Reuters) - ProMIS Neurosciences Inc

* ProMIS Neurosciences designates PMN330 as third, validated lead product for development in alzheimer’s disease

* ProMIS Neurosciences inc - “PMN310 is on track for initiation of clinical trials in 2019.” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below